CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|March 1, 2015
- BioPharm International-03-01-2015
- Volume 28
- Issue 3
Polyethylene Biocontainer Increases Customizability
Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio.
Advertisement
Meissner’s TepoFlex is a polyethylene biocontainer designed for secure handling and it is part of the One-Touch single-use systems portfolio. Available in standard assembly designs of 50 mL–1000 L, the biocontainers can be fitted with customized tube lengths, connectors, and end fittings.
To fit existing rigid outer containers and biomanufacturing systems, custom biocontainers can be designed. The biocontainers, which serve applications from process development through production, are designed with the same materials throughout the entire portfolio to streamline scale-up efforts when ordering new parts.
Articles in this issue
over 11 years ago
USP Publishes Monoclonal Antibody Guidelinesover 11 years ago
Maintaining the Stability of Biologicsover 11 years ago
Springing Forwardover 11 years ago
Reinventing the Cold Chain in a High-Stakes Marketover 11 years ago
A Robust CAPA System for a Global Supply Chainover 11 years ago
CMOs Plan for Capacity Expansionsover 11 years ago
Vaccine Development and Production Challenges Manufacturersover 11 years ago
Detecting Protein Aggregates and Evaluating their Immunogenicityover 11 years ago
Re-use of Protein A Resin: Fouling and Economicsover 11 years ago
SEC in the Modern Downstream Purification ProcessAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement